AIDS Alert Archives – April 1, 2005
April 1, 2005
View Archives Issues
-
New York City case of multidrug-resistant, rapid AIDS progression baffling
HIV physicians and public health officials say the recent discovery of a man in his mid-40s with both rapidly progressing AIDS and a highly resistant strain could portend an ominous turn in the epidemic, particularly in light of evidence that the transmission of antiretroviral resistant HIV is increasing in some cities. -
DOHMH recommendations for treating at-risk patients
In a medical health alert issued Feb. 11, 2005, the New York City Department of Health and Mental Hygiene (DOHMH) issued these recommendations for providers in New York City, where its believed a three-drug class resistant HIV (3DHR HIV) strain may become more prevalent. -
President’s budget concerns advocates
President George W. Bush expressed support for the reauthorization of the Ryan White Care Act in his State of the Union address, but his budget for the 2006 fiscal year provided mostly flat funding. AIDS advocates say cuts in prevention activities are a sign that trouble is ahead for state budgets and AIDS service organizations struggling to provide prevention, care, and other services to growing HIV populations. -
CDC releases detailed guidelines for PEP use
While post-exposure prophylaxis (PEP) has been available to medical employees and first responders for years, public health officials have routinely dismissed the possibility of extending PEP to the general public, citing the inefficiency of its use even after potential exposure to HIV from rape. -
Adherence tips included in IDSA care blueprint
The first guidelines written explicitly for the primary care of HIV patients include two pages about antiretroviral adherence, demonstrating how management of HIV disease increasingly is incorporating behavioral factors with medical practice. -
FDA Notifications
BMS issues letter about omeprazole, Copackaged drug regimen approved for PEPFAR, FDA issues final guidance on nucleic acid tests, Consumers warned about unapproved test kits, Roche issues drug interaction warning.